Paper27366142
Recent developments on potential new applications of emetine as anti-cancer agent.
Uzor PF. EXCLI J, 2016. Cited by 13 papers, by iCite.
Cite this record
ConductScience Library. Recent developments on potential new applications of emetine as anti-cancer agent. Papers, record 27366142. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/27366142
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References31
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 4929936 | Experience with emetine hydrochloride (NSC 33669) as an antitumor agent. | Cancer | 1971 | https://conductscience.org/library/papers/4929936 | PubMed |
| 2 | 24747809 | Efficacy of multi-functional liposomes containing daunorubicin and emetine for treatment of acute myeloid leukaemia. | Eur J Pharm Biopharm | 2014 | https://conductscience.org/library/papers/24747809 | PubMed |
| 3 | 24045224 | Emetine dihydrochloride: a novel therapy for bladder cancer. | J Urol | 2014 | https://conductscience.org/library/papers/24045224 | PubMed |
| 4 | 24213797 | Emetine enhances the tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of pancreatic cancer cells by downregulation of myeloid cell leukemia sequence-1 protein. | Oncol Rep | 2014 | https://conductscience.org/library/papers/24213797 | PubMed |
| 5 | 25310746 | The alkaloid emetine sensitizes ovarian carcinoma cells to cisplatin through downregulation of bcl-xL. | Int J Oncol | 2015 | https://conductscience.org/library/papers/25310746 | PubMed |
| 6 | 5272222 | Chemotherapy of neoplasia (cancer) with dehydroemetine. | J Trop Med Hyg | 1969 | https://conductscience.org/library/papers/5272222 | PubMed |
| 7 | 26278973 | Molecular docking study of natural alkaloids as multi-targeted hedgehog pathway inhibitors in cancer stem cell therapy. | Comput Biol Chem | 2016 | https://conductscience.org/library/papers/26278973 | PubMed |
| 9 | 20061395 | Three new O-methyltransferases are sufficient for all O-methylation reactions of ipecac alkaloid biosynthesis in root culture of Psychotria ipecacuanha. | J Biol Chem | 2010 | https://conductscience.org/library/papers/20061395 | PubMed |
| 10 | 4160874 | Dehydroemetine in chronic leukaemia. | Lancet | 1966 | https://conductscience.org/library/papers/4160874 | PubMed |
| 12 | 21228475 | Molecular cloning of an O-methyltransferase from adventitious roots of Carapichea ipecacuanha. | Biosci Biotechnol Biochem | 2011 | https://conductscience.org/library/papers/21228475 | PubMed |
| 13 | 26798435 | Antitumor effects of the benzophenanthridine alkaloid sanguinarine: Evidence and perspectives. | World J Gastrointest Oncol | 2016 | https://conductscience.org/library/papers/26798435 | PubMed |
| 14 | 4705155 | A phase I study of emetine hydrochloride (NSC 33669) in solid tumors. | Cancer | 1973 | https://conductscience.org/library/papers/4705155 | PubMed |
| 15 | 22988474 | Alkaloids isolated from natural herbs as the anticancer agents. | Evid Based Complement Alternat Med | 2012 | https://conductscience.org/library/papers/22988474 | PubMed |
| 16 | 890691 | Whatever happened to NSC--? An analysis of clinical results of discontinued anticancer agents. | Cancer Treat Rep | 1977 | https://conductscience.org/library/papers/890691 | PubMed |
| 17 | 12804695 | Natural products for cancer prevention: a global perspective. | Pharmacol Ther | 2003 | https://conductscience.org/library/papers/12804695 | PubMed |
| 18 | 20813864 | Emetine promotes von Hippel-Lindau-independent degradation of hypoxia-inducible factor-2α in clear cell renal carcinoma. | Mol Pharmacol | 2010 | https://conductscience.org/library/papers/20813864 | PubMed |
| 19 | 26332055 | Emetine inhibits migration and invasion of human non-small-cell lung cancer cells via regulation of ERK and p38 signaling pathways. | Chem Biol Interact | 2015 | https://conductscience.org/library/papers/26332055 | PubMed |
| 20 | 4299101 | Inhibitors of protein biosynthesis. V. Effects of emetine on protein and nucleic acid biosynthesis in HeLa cells. | J Biol Chem | 1968 | https://conductscience.org/library/papers/4299101 | PubMed |
| 21 | 26835873 | Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy. | Prostate | 2016 | https://conductscience.org/library/papers/26835873 | PubMed |
| 22 | 22848307 | Emetine regulates the alternative splicing of caspase 9 in tumor cells. | Oncol Lett | 2011 | https://conductscience.org/library/papers/22848307 | PubMed |
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42634207 | Emetine and Its Derivatives as Anticancer Agents Targeting the PI3K/AKT/mTOR Pathway: A Narrative Review of Mechanisms, Pharmacology, and Clinical Insights. | J Cell Mol Med | 2026 | https://conductscience.org/library/papers/42634207 | PubMed |
| 42337289 | Emetine dihydrochloride suppresses the invasiveness and motility of hepatocellular carcinoma cells through MAPK pathway inhibition and Twist1 protein destabilization. | Sci Rep | 2026 | https://conductscience.org/library/papers/42337289 | PubMed |
| 38187064 | Oral squamous cell carcinoma cancer stem cells have different drug sensitive to pharmacological NFκB and histone deacetylation inhibition. | Am J Cancer Res | 2023 | https://conductscience.org/library/papers/38187064 | PubMed |
| 37081916 | Phytochemical composition and antioxidant activities of some wild edible plants locally consumed by rural communities in northern Uganda. | Front Nutr | 2023 | https://conductscience.org/library/papers/37081916 | PubMed |
| 36941385 | Emetine, a small molecule natural product, displays potent anti-gastric cancer activity via regulation of multiple signaling pathways. | Cancer Chemother Pharmacol | 2023 | https://conductscience.org/library/papers/36941385 | PubMed |
| 35626133 | A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35626133 | PubMed |
| 35187519 | Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label treatment. | Cell Genom | 2022 | https://conductscience.org/library/papers/35187519 | PubMed |
| 33261173 | Emetine Is Not Ipecac: Considerations for Its Use as Treatment for SARS-CoV2. | Pharmaceuticals (Basel) | 2020 | https://conductscience.org/library/papers/33261173 | PubMed |
| 31964796 | Lead Optimization of Dehydroemetine for Repositioned Use in Malaria. | Antimicrob Agents Chemother | 2020 | https://conductscience.org/library/papers/31964796 | PubMed |
| 31436297 | Emetine exhibits anticancer activity in breast cancer cells as an antagonist of Wnt/β‑catenin signaling. | Oncol Rep | 2019 | https://conductscience.org/library/papers/31436297 | PubMed |
| 29333136 | Highlight report: The relationship of DNA copy number alterations and mRNA levels in cancer. | EXCLI J | 2017 | https://conductscience.org/library/papers/29333136 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/27366142
GET https://conductscience.org/api/papers/v1/27366142/references?page=2